The debate highlighted promising PTMs like K280 acetylation and O-GlcNAcylation but didn't resolve which modifications can be selectively targeted without affecting physiological tau function. This specificity gap is critical for developing PTM-based therapeutics that avoid broad cellular toxicity.
Source: Debate session sess_SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd_20260412-091129 (Analysis: SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd)
Selective HDAC6 inhibitors (T-518, Tubastatin A, ACY-1215) simultaneously increase α-tubulin acetylation to restore microtubule stability disrupted by tau pathology, reduce tau hyperphosphorylation through improved vesicular transport, and enhance autophagic clearance of aggregated tau. The selectivity of HDAC6 over other HDACs avoids broad transcriptional dysregulation.
No AI visual card yet
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
13 citations7 with PMIDValidation: 50%7 supporting / 6 opposing
✓For(7)
No supporting evidence
No opposing evidence
(6)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
7
4
2
MECH 7CLIN 4GENE 2EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
T-518, an orally active selective HDAC6 inhibitor,…
T-518, an orally active selective HDAC6 inhibitor, shows therapeutic potential in AD and tauopathy mouse model…▼
T-518, an orally active selective HDAC6 inhibitor, shows therapeutic potential in AD and tauopathy mouse models with favorable pharmacodynamics and superior HDAC6 selectivity over other HDACs
Tubastatin A/ACY-1215 improves cognition in AD transgenic mice by promoting tubulin acetylation, reducing Aβ p…▼
Tubastatin A/ACY-1215 improves cognition in AD transgenic mice by promoting tubulin acetylation, reducing Aβ production, and facilitating autophagic clearance of hyperphosphorylated tau without obvious adverse effects
Tau itself is an inhibitor of deacetylase HDAC6 function, creating a pathological feedback loop where tau accu…▼
Tau itself is an inhibitor of deacetylase HDAC6 function, creating a pathological feedback loop where tau accumulation further disrupts microtubule acetylation homeostasis
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-13 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Novel Therapeutic Hypotheses: Disease-Specific Tau PTM Targets
Hypothesis 1: P300/CBP Acetyltransferase Inhibition to Block K280 Acetylation While Preserving Physiological Acetylation
Target: EP300 (p300)
Description: p300-mediated acetylation at K280 is disease-specific and blocks tau microtubule binding. Unlike pan-HDAC inhibitors, selective p300 inhibition with C646 or A-485 would block this pathogenic acetylation while preserving physiological acetylation at other sites (K163, K174) and avoiding broad deacetylase disruption that causes cytotoxicity.
**Supporting Evidence
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation of Disease-Specific Tau PTM Therapeutic Hypotheses
Enzymatic Specificity Gap: The claim that p300 selectively mediates K280 acetylation lacks direct biochemical characterization. p300/CBP have overlapping substrate specificity and have been shown to acetylate multiple sites on tau beyond K280 (PMID: 25651121). Demonstrating selective p300-mediated K280 acetylation in human brain tissue has not been conclusively established.
Inhibitor Selectivity Concerns: While A-4
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Domain Expert Evaluation: Disease-Specific Tau PTM Drug Targets
Executive Summary
Of the seven hypotheses, none currently meet all criteria for an optimal therapeutic target: disease-specific causality, target druggability with selective chemical matter, acceptable safety window, and demonstrated CNS penetration. However, two hypotheses (P300 inhibition, PRMT5 inhibition) have sufficient chemical matter and target validation to justify near-term investment with appropriate risk mitigation. Four hypotheses require significant chemical matter development or causality validation. One
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼